NEW CASE STUDY Unlocking the power of process analytical technology to boost downstream operations    Dive in today!
Contact Us
Contact Us

AGC Biologics

AGC Biologics to support Novelty Nobility for antibody drug candidate

2 min read

AGC Biologics Partners with Novelty Nobility for Cell Line Development and Phase I Preparations of Antibody Drug Candidate

May 5, 2025 at 4:00 PM
Mammalian & mAbs Press Release
Read press release
AGC Biologics Yokohama Facility begins GMP production in 2027

2 min read

AGC Biologics Strengthens Single-Use Technology Network, Adds 5,000 L Vessels from Thermo Scientific to New Yokohama, Japan Facility

April 7, 2025 at 3:51 PM
Mammalian & mAbs Press Release
Read press release
AGC Biologics announces new cell and gene business division

3 min read

AGC Biologics Launches New Dedicated Cell and Gene Business Division

April 2, 2025 at 12:25 PM
Cell & Gene Therapy Press Release
Read press release

1 min read

AGC Biologics Honored at CDMO Leadership Awards for Excellence in Quality, Biologics and Cell and Gene Therapies

March 10, 2025 at 2:41 PM
Cell & Gene Therapy Mammalian & mAbs Press Release Microbial
Read press release
Adaptimmune and AGC Biologics Partnership

2 min read

AGC Biologics’ Milan Site to Prepare Lentiviral Vector Commercial Manufacturing for Adaptimmune’s Lete-Cel Product

January 16, 2025 at 5:30 AM
Cell & Gene Therapy Press Release
Read press release
AGC Biologics’ Cell and Gene Center of Excellence expands exosome work with new project.

2 min read

Pandorum Partners with AGC Biologics to Support Clinical Manufacturing of Exosome-Based Kuragenx, a Treatment of Ulcerative Corneal Blindness

January 9, 2025 at 7:00 AM
Cell & Gene Therapy Press Release
Read press release
New leadership roles to drive operational readiness and regional growth for the company in Japan

1 min read

AGC Biologics Announces Leadership Updates Amid Groundbreaking of New Yokohama Site

December 22, 2024 at 6:00 PM
Press Release Business Updates
Read press release
AGC Biologics CMC Jumpstart™ Program Offers Platform Assessments

2 min read

New AGC Biologics CMC Jumpstart™ Program Offers CGT Developers Viral Vector Platform Assessments that Control Costs and Analyze Feasibility

December 18, 2024 at 9:15 AM
Cell & Gene Therapy Press Release
Read press release
Autolus and AGC Biologics

2 min read

AGC Biologics to Manufacture LVV for CAR-T Therapy Approved by FDA for Autolus Therapeutics’ AUCATZYL®

December 11, 2024 at 9:00 AM
Cell & Gene Therapy Press Release
Read press release

2 min read

AGC Biologics Appoints Alberto Santagostino as new Chief Executive Officer

October 28, 2024 at 3:00 AM
Press Release Business Updates
Read press release
Prev 1 2 3 4 Next